Program

The 13th International HBV Cure Workshop 2026 will be held in Denver, Colorado on November 4, 2026, right before The Liver Meeting® (TLM) 2026 by AASLD. This highly anticipated workshop brings together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Since its inception in 2014, the International HBV Cure Workshop has been a pivotal scientific platform aimed at accelerating the progress towards finding a cure for HBV.

The HBV treatment landscape is experiencing significant transformations and is on the brink of a paradigm shift. The emergence of numerous new treatment options brings great hope for reducing the disease burden, simplifying treatment protocols, and potentially curing and eradicating HBV infection. To optimize curative treatments for HBV, distinguished speakers from around the world will present the latest therapeutic options.

Wednesday, November 4, 2026
7:30 AM - 8:00 AM																AM Coffee & Pastries
8:00 AM - 8:10 AM																Opening remarks Adam Gehring, Toronto Centre for Liver Disease
8:10 AM - 9:40 AM																SESSION I - Biomarkers 08:10 – 08:30 Baseline HBsAg levels in HBsAg loss, functional cure and setpoint after therapy discontinuation 08:30 – 08:50 Partial cure and long-term outcomes: What data do we need? 08:50 – 09:10 New virological and immunological biomarkers to improve our understanding on target engagement and functional cure prediction. 09:10 – 09:40 Discussion Man-Fung Yuen, The University of Hong Kong / Queen Mary Hospital Fabien Zoulim, Lyon University Jordan Feld, University Health Network Harry Janssen, Erasmus MC, University Medical Center Rotterdam Pietro Lampertico, University of Milan Maura Dandri, University Medical Center Hamburg-Eppendorfufessor
9:40 AM - 10:00 AM																AM BREAK
10:00 AM - 11:30 AM																SESSION II - Managing Patient Populations 10:00 – 10:20 HBV cure in special populations 10:20 – 10:50 Clinical perspective of novel HBV combination therapies: Efficacy vs. AEs & Complexity? 10:50 – 11:10 How much are patients willing to accept to achieve durable functional cure? 11:10 – 11:30 Discussion Fabien Zoulim, Lyon University Norah Terrault, Keck School of Medicine of USC Chari Cohen, Hepatitis B Foundation Carla Coffin, University of Calgary Mark Sulkowski, Johns Hopkins University School of Medicine
11:30 AM - 12:30 PM																Lunch Break
12:30 PM - 2:30 PM																SESSION III - Company presentations • 12:30 – 12:40 Brief Introduction of industry talks • 12:40 – 12:50 Evidence of vaccine efficacy in a heterogeneous patient population • 12:50 – 13:00 Durable HBsAg decline following a single injection of VRON-0200 • 13:00 – 13:10 Opportunities for bepirovirsen re-treatment based on modeling of existing data • 13:10 – 13:20 Functional cure rates in treatment naive vs. treatment experienced patients receiving AHB-137 • 13:20 – 13:30 Insights into sustained HBsAg reduction after discontinuation of Pevifoscovir • 13:30 – 13:40 Antiviral efficacy of epigenetic editor Tune-401 • 13:40 – 13:50 Antiviral efficacy of arcus nuclease, PBGENE-HBV, and editing profiles observed in patient biopsies. • 13:50 – 14:30 Discussion Dr. Sue Currie, Virion Therapeutics Frida Abramov, Gilead Sciences Kendra Congdon, Tune Therapeutics Dr. Tse-I Lin, Aligos Therapeutics Man-Fung Yuen, The University of Hong Kong / Queen Mary Hospital Mark Sulkowski, Johns Hopkins University School of Medicine Ahmed Nader Guofeng Cheng, AusperBio Therapeutics Inc.
2:30 PM - 3:00 PM																PM BREAK
3:00 PM - 4:20 PM																SESSION IV - Round table topics 15:00 – 15:20 Antisense oligonucleotides as the backbone for new combination therapies 15:20 – 15:40 How much would effective immunotherapy impact functional cure rates? 15:40 – 16:20 Discussion Carla Coffin, University of Calgary Adam Gehring, Toronto Centre for Liver Disease
4:20 PM - 4:30 PM																Closing Remarks Harry Janssen, Erasmus MC, University Medical Center Rotterdam
5:00 PM - 6:30 PM																The Forum for Collaborative Research-HBV Forum 17
6:30 PM - 8:30 PM																NETWORKING RECEPTION